Effects of lithium gammalinolenate on the perfusion of liver and pancreatic tissues in pancreatic cancer

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3729-3736

  Kairemo, Kalevi J A ^a   Jekunen, Antti P ^a   Korppi Tommola, E Tapani ^a   Pyrhönen, Seppo O ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cancer therapy; Gammalinolenic acid; Pancreas neoplasms; Pancreas perfusion; Radionuclide imaging

Indexed keywords

CA 19-9 ANTIGEN; GAMMA LINOLENIC ACID; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TECHNETIUM 99M; TUBULIN; VINCA ALKALOID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG UPTAKE; FEMALE; HEART; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER METASTASIS; LIVER PERFUSION; LUNG; MALE; MUSCLE; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PANCREAS PERFUSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SALIVARY GLAND; SCINTISCANNING; SPINE; SPLEEN; THYROID GLAND; TISSUE PERFUSION;

ADMINISTRATION, ORAL; AGED; BLOOD-BRAIN BARRIER; FEMALE; GAMMA-LINOLENIC ACID; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; TECHNETIUM TC 99M SESTAMIBI;

EID: 0031441114     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Casper ES: Comments and critique: Pancreatic cancer: how can we progress? Eur J Cancer 29A: 171-172, 1993.
2. Williamson RCN: Pancreatic cancer: the greatest oncological challenge. Br Med J 288: 445-446, 1988.
3. Carter DC: Cancer of the pancreas. Curr Opin Gastroenterol 5: 716-722, 1989.
4. Begin ME, Das UN, Ells G and Horrobin DF: Selective killing of human cancer cells by polyunsaturated fatty acids. Prostaglandins Leukotrienes Med 19: 177-186, 1985.
5. Begin ME, Ells G and Horrobin DF: Polyunsaturated fatty acid induced cytotoxicity against tumour cells and its relationship to lipid peroxidation. J Natl Cancer Inst 80: 188-194, 1988.
6. Fujiwara F, Todo S and Imashuku S: Antitumour effect of GLA on cultured human neuroblastoma cells. Prostaglandins Leukotrienes Med 75: 15-34, 1984.
7. Anel A, Navel J and Desportes P: Increased cytotoxicity of polyunsaturated fatty acids on human tumoural B and T cell lines. Leukaemia 6: 690-688, 1992.
8. Begin ME, Das UN and Ells G: Cytotoxic effects of EFAs in mixed cultures of normal and malignant human cells. Prog Lipid Res 25: 573-576, 1986.
9. Karmali RA, Marsch J and Fuschs C: Effect of dietary enhancement with GLA upon growth of R3230AC mammary adenocarcinoma. J Nutr Growth Cancer 2: 41-51, 1985.
10. Pritchard GA, Jones DL and Mansel RE: Lipids in breast carcinogenesis. Br J Surg 76: 1069-1073, 1989.
11. De Bravo MG, Schinella G, Tournier H and Quintans, C: Effects of dietary gamma and alpha linoleic acid on a human lung carcinoma growth in nude mice. Med Sci Res 22: 667-668, 1994.
12. Leary WP, Robinson KM, Booyens J and Dippenaar N: Some effects of gamma-linolenic acid on cultured human oesophageal carcinoma cells. S Afr Med J 62: 681-683, 1982.
13. Dippenaar N, Booyens J, Fabbri D, Engelbrecht P and Katzeff IE: The reversibility of cancer: evidence that malignancy in human hepatoma cells is gamma-linolenic acid deficiency-dependent. S Afr Med J 62: 683-685, 1982.
14. Mengeaud V, Nano JL, Fournel S and Rampal P: Effects of eicosapentaenoic acid, gamma-linolenic acid and prostaglandin E1 on three human colon carcinoma cell lines. Prostaglandins Leukot Essent Fatty Acids 47: 313-319, 1992.
15. Dippenaar N, Booyens J, Fabbri D and Katzeff IE: The reversibility of cancer: evidence that malignancy in melanoma cells is gamma-linolenic acid deficiency dependent. S Afr Med J 62: 505-509, 1982.
16. Falconer JS, Ross JA, Fearon KCH, Hawkins RA, O'Riordain MG and Carter DC: Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro human pancreatic cancer cell lines. Br J Cancer 69: 826-832, 1994.
17. Horrobin DF: Essential fatty acids, lipid peroxidation and cancer. In: Omega-6 Essential Fatty Acids: Pathophysiology and roles in Clinical Medicine 1990, pp 351-379.
18. Fearon KCH, Falconer JS, Ross JA, Carter DC, Hunter JO, Reynolds PD and Tuffnell Q: An open phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res 16: 867-874, 1996.
19. Burns CP and Spector AA: Membrane fatty acid modification in tumour cells: a potential therapeutic adjunct. Lipids 22: 178-184, 1987.
20. Roos DS and Choppin PW: Tumourgenicity of cell lines with altered lipid composition. Proc Natl Acad Sci USA 87: 7622-7626, 1984.
21. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH and Speizer FE: Dietary fat and the risk of breast cancer. N Eng J Med 316: 22-28, 1987.
22. Caner B, Kitapcl M, Unlü M, Erbengi G, Calikoglu T, Gogus T and Bekdik C: Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. J Nucl Med 33: 319-324, 1992.
23. Vattimo A, Bertelli P, Cintorino M, Burroni L, Volterrani D and Vella A: Identification of Hürthle cell tumor by single-injection, double-phase scintigraphy with technetium-99m-sestamibi. J Nucl Med 36: 778-782, 1995.
24. Bom HS, Kim JY, Kim YC, Choi IS and Park KO: Tc-99m MIBI uptake in simultaneous thyroid and lung cancers. Clin Nucl Med 19: 604-606, 1994.
25. Campeau RJ, Kronemer KA and Sutherland CM: Concordant uptake of Tc-99m sestamibi and Tl-201 in unsuspected breast tumor. Clin Nucl Med 17: 936-937, 1992.
26. Scott AM, Kostakoglu L, O'Brien JP, Straus DJ, Abdel-Dayem HM and Larson SM: Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma. J Nucl Med 33: 1396-1398, 1992.
27. Packard AB, Kronauge JF, Limpa-Amara N, Lampson L, O'Tuama LA and Jones AG: Tumor uptake of 99mTc-MIBI and 201Tl by a 9L gliosarcoma brain tumor model in rats. Nucl Med Biol 20: 773-776, 1993.
28. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A and Jones AG: Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50: 2198-2202, 1990.
29. Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL and Piwnica-Worms-D: Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33: 1516-1522, 1992.
30. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752, 1995.
31. Purasiri P, Murray A, Richardson S, Heys SD, Horrobin D and Eremin O: Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci (Colch) 87: 711-717, 1994.
32. Cantrill RC, Ells GW, Chisholm KA, Hughes BJ and Horrobin DF: Variations in temperature and oxygen content do not alter levels of thiobarbiturate reactive material in human breast tumour cells (ZR-75-1) incubated with gamma-linolenic acid. Anticancer Res 13: 1461-1464, 1993.
33. Kinchington D, Randall S, Winther M and Horrobin D: Lithium gamma-linolenate-induced cytotoxicity against cells chronically infected with HIV-1. FEBS Lett 330: 219-221, 1993.
34. Hopewell JW, Robbins ME, van den Aardweg GJ, Morris GM, Ross GA, Whitehouse E, Horrobin DF and Scott CA: The modulation of radiation-induced damage to pig skin by essential fatty acids. Br J Cancer 68: 1-7, 1993.
35. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, Kajiyama T, Ohshio G, Imamura M and Konishi J: Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 195: 345-352, 1995.
36. Benyounes H, Smith FW, Campbell C, Evans NT, Norton MY, Mikecz P, Heys SD, Bruce D, Eremin O and Sharp PF: Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Nucl Med Commun 16: 575-580, 1995.
37. Åhlström H, Eriksson B, Bergström M, Bjurling P, Långström B and Öberg K: Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195: 333-337, 1995.
38. Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M and Konishi J: Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 36: 229-235, 1995.
39. 68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors. Horm Metab Res 26: 453-459, 1994.
40. Lamberts SW, Bakker WH, Reubi JC and Krenning EP: Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323: 1246-1249, 1990.
41. Bergström M, Eriksson B, Öberg K, Sundin A, Åhlström H, Lindner KJ, Bjurling P and Långström B: In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 37: 32-37, 1996.
42. Kubo S, Yamamoto K, Magata Y, Iwasaki Y, Tamaki N, Yonekura Y and Konishi J: Assessment of pancreatic blood flow with positron emission tomography and oxygen-15 water. Ann Nucl Med 5: 133-138, 1991.